Laurus Labs has been one of India’s standout stock market stories of 2026 — and the numbers tell you exactly why. The pharma-biotech company reported 148% growth in net profit to ₹889 crore in FY26. Revenue jumped 23% to ₹6,813 crore. EBITDA margins expanded by 6.7 percentage points to 26.8%. And the stock has surged roughly 30% year-to-date, reaching a record high of ₹1,162. Its market cap has more than doubled in one year to ₹78,336 crore.
What Is Driving This Growth?
The CDMO machine is humming. The Contract Development and Manufacturing Organisation (CDMO) business — where Laurus manufactures complex active pharmaceutical ingredients for global drug companies’ new molecules — grew 36% in FY26 to ₹2,080 crore. Small molecules CDMO grew 38% to ₹1,896 crore, driven by late-stage pipeline projects and commercial supplies for new chemical entities (NCEs) — essentially breakthrough new drugs from Western pharmaceutical companies.
This is the high-value, high-margin business. Unlike generic manufacturing (where you compete on price), CDMO is a partnerships business — Laurus co-develops with global pharma companies, gets exclusive contracts, and earns margins of 30–35% versus 15–20% for generics.
ARV (antiretroviral) business remains a stable cash cow. Laurus is one of the world’s largest manufacturers of HIV/AIDS medicines for global health programmes. ARV revenues stayed strong at around ₹2,800 crore — providing predictable cash flows that fund CDMO expansion.
Bio division growing. Laurus Bio (fermentation-based biologics) grew 15% to ₹184 crore. A new 400 KL fermentation facility in Vizag, backed by Eight Roads Ventures and F-Prime Capital (Fidelity’s venture arm), is under construction and expected complete by end 2026.
The ₹3,000 Crore Capex — What It Buys
Management raised its 2-year capex plan to ₹3,000 crore, focused on:
- Unit 7 — large greenfield CDMO manufacturing site
- Peptide manufacturing block (commercial scale ready Q2 FY27)
- Fermentation capacity expansion for Laurus Bio
- Formulation facility with KRKA (Slovenian pharma JV) in Hyderabad
- Animal health and crop protection chemicals capacity
The key message from management: this is demand-led capex, not speculative. Laurus has visibility into customer contracts before it builds capacity.
Valuation: Is It Expensive Now?
At ₹1,162/share, Laurus trades at approximately 14.8x book value and 87x FY26 earnings. That sounds rich until you look at the forward picture. Analysts at major brokerages project FY27 PAT of ₹1,200–1,400 crore — 35–55% growth from FY26’s ₹889 crore. On FY27E earnings, the stock trades at 55–65x — still a premium, but defensible for a company growing 35–50% annually with strong free cash flows and a clear demand runway.
Brokerage targets: ₹1,280 (Buy, 62x 12-month forward). AGM is July 2, 2026 — watch for management guidance on FY27 CDMO pipeline.
Risks to Watch
- CDMO pipeline concentration: A single large customer losing a clinical trial could hurt revenues disproportionately
- ARV price pressure from competition — though Laurus is among the most cost-efficient producers globally
- Currency risk: significant USD revenues, but rupee weakening is actually a tailwind
- The huge capex increases depreciation charges from FY27, which will moderate PAT growth even if EBITDA stays strong
Should You Buy, Hold, or Book Profits?
If you have been holding since ₹600–800: You have a 45–90% gain. Consider booking 25–30% to reduce concentration risk and let the rest run. Laurus’s FY27–28 story is not over.
Fresh buy at ₹1,100–1,200: Possible with a 2-year view if you believe India’s CDMO sector will grow to $20 billion by 2030 (it is currently ~$3 billion). Laurus is one of the two or three companies that will dominate that growth alongside Divi’s Labs and Syngene.
Avoid if your horizon is under 12 months — the stock has had a massive run and near-term consolidation is normal after a 30% year-to-date move.
Disclaimer: Not investment advice. Please consult a SEBI-registered advisor.
